BCG for Therapeutic Use Phase Ⅲ Clinical Trial

NCT06747455 | Active Not Recruiting Phase 3

• 1 other identifier: LKM-2024-BCG01
• Study Type: interventional
• Target: 439
• Locations: 1 country
• Sites: 1

Brief Summary

Research topic: A randomized, double-blind, active-controlled, multicenter phase III clinical trial evaluating the efficacy and safety of therapeutic BCG for the prevention of postoperative recurrence of non-muscle-invasive bladder cancer in people aged 18 years and older. The name of the drug: Bacillus Calmette-Guérin for treatment(BCG). Clinical indications: It is used for the treatment of bladder carcinoma in situ and the prevention of recurrence, and for the prevention of recurrence of bladder papilloma after transurethral resection in Ta or T1 stage. This product is not used for papillomas beyond the T1 stage. Study population: Patients aged 18 years and above with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) who have undergone transurethral bladder tumor resection. Objectives: Primary Objectives: To assess the effectiveness of BCG for therapeutic use in the adjuvant treatment of intermediate- and high-risk NMIBC after transurethral resection of bladder tumors. Secondary Purpose: To assess the safety of the therapeutic BCG vaccine in the adjuvant treatment of intermediate- and high-risk NMIBC after transurethral resection of bladder tumors. Other purposes: To assess the pharmacodynamic (PD) profile of BCG for therapeutic use in the adjuvant treatment of intermediate- and high-risk NMIBC after transurethral resection of bladder tumors. Study design: This study adopts a randomized, double-blind, active-controlled, multi-center trial design, including three phases: screening period, treatment period and follow-up period. In this study, 438 subjects will be randomly assigned to the experimental group and the control group in a 1:1 ratio, with 219 patients in both the experimental group and the control group, and stratified according to the baseline risk level (high-risk/intermediate-risk) and whether or not to perform urine PD sample collection (yes/no).

Conditions

BCG

Keywords

Bacillus Calmette-Guérin for treatment; Bladder cancer.

Outcome Measures

Primary Outcomes (7)

• 1-year RFS%

  To assess the proportion of participants who were free of recurrence or death (whichever occurs first) from randomisation up to 1 year.

  Up to 1 year after randomization

• Safety endpoints

  Incidence of all AEs

  30 days after the last dose

• Safety endpoints

  Incidence of all SAEs

  30 days after the last dose

• Safety endpoints

  Any clinically significant abnormalities of vital signs during the trial

  30 days after the last dose

• Safety endpoints

  Any clinically significant abnormalities found in the physical examination during the trial

  30 days after the last dose

• Safety endpoints

  Any clinically significant abnormalities in laboratory tests during the trial

  30 days after the last dose

• Safety endpoints

  Any clinically significant abnormalities in the electrocardiogram (ECG) examination during the trial

  30 days after the last dose

Secondary Outcomes (3)

• 2-years RFS%

  Up to 2 years after randomization

• 1-year PFS%

  Up to 1 year after randomization

• 2-years PFS%

  Up to 2 years after randomization

Other Outcomes (6)

• To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC

  The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration

• To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC

  The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration

• To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC

  The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration

Study Arms (2)

Experimental group

EXPERIMENTAL

Common name: BCG for Therapeutic Use Specification: 60mg/bottle. Each bottle contains 60mg of BCG, and the number of viable bacteria per 1mg BCG should not be less than 1.0×10\^6CFU. Expiration date: 24 months. Production unit: Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd.

Drug: BCG for Therapeutic Use

Control group

ACTIVE COMPARATOR

Common name: BCG for Therapeutic Use ( BI SAI JI ) Specification: 60mg (6.0×10\^7CFU)/bottle. Each bottle contains 60mg of BCG, and the number of viable bacteria per 1mg BCG should not be less than 1.0×10\^6CFU. Expiration date: 18 months. Production unit: Chengdu Institute of Biological Products Co., Ltd.

Drug: BCG for Therapeutic Use ( BI SAI JI )

Interventions

BCG for Therapeutic Use DRUG

After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were given intravesical infusion (experimental drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.

Experimental group

BCG for Therapeutic Use ( BI SAI JI ) DRUG

After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were administered intravesical infusion (control drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.

Control group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Age≥ 18 years old, male or female;
• \. According to the Guidelines for the Diagnosis and Treatment of Bladder Cancer (2022 Edition), the initial histological diagnosis of intermediate- and high-risk non-muscle-invasive urothelial carcinoma of the bladder (T1, Ta or Tis) and the need for BCG bladder infusion adjuvant therapy is evaluated;
• \. Patients undergoing transurethral bladder tumor resection need to meet the requirements of all tumors to have no visible tumors after surgery. This study can also enroll patients who need a second electroresection, subjects who meet the secondary electroresection criteria are recommended to undergo secondary electroresection and should be included in the study after comprehensive evaluation based on the two pathological results (BCG perfusion for treatment should be carried out within 2\~12 weeks after surgery, cystoscopy should be added more than 4 weeks after surgery to ensure that there is no visible tumor after surgery, and the subjects who underwent secondary resection should be calculated based on the postoperative time of the second electroresection); Note: The criteria for the second resection: (1) the first TURBt is insufficient; (2) the first electrosection of non-myometrial tissue specimens; (3) T1 tumors; (4) High-grade (G3) tumors, except for carcinoma in situ. The second resection is recommended to be performed within 2-6 weeks after the first resection, and no other perfusion therapy is allowed except for the bladder infusion chemotherapy drugs immediately after the first and second resection;
• \. Eastern Cooperative Oncology Group (ECOG) score (see Appendix 1 for details): 0\~2 points;
• \. At screening, clinical laboratory tests meet the following characteristics:
• Blood routine: no use of hematopoietic growth factors or blood transfusion support within 14 days before randomization, including: absolute neutrophil count (ANC) ≥1500/mm\^3 or ≥1.5×10\^9/L; Platelets≥ 100000/mm\^3 or 100×10\^9/L; Hemoglobin ≥ 9 g/dL.
• Liver function: total bilirubin ≤ 1.5× upper limit of normal range (ULN), subjects with Gilbert's syndrome require total bilirubin \<3×ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN.
• Renal function: defined as creatinine clearance estimated according to the Cockcroft Gault formula (Appendix 2) ≥ 30mL/min;
• Coagulation function: activated partial thromboplastin time (APTT) ≤ 1.5×ULN, and the international normalized ratio (INR) ≤ 1.5×ULN.
• \. Voluntarily participate in this trial, with full informed consent and signed written informed consent.

You may not qualify if:

• \. Those who have immunodeficiency or damage (such as AIDS patients), are using immunosuppressive drugs, steroid hormones, etc., which may cause systemic BCG disease reaction (other hormones such as patients who are given corresponding hormone therapy after thyroid/adrenal resection can be enrolled);
• \. Those who are allergic to BCG and its excipients;
• \. Active tuberculosis, those who are receiving or have received anti-tuberculosis treatment within 6 months before screening;
• \. Patients with severe cardiovascular and cerebrovascular, liver, lung, and kidney diseases at the time of screening;
• \. Patients with histologically confirmed muscle-invasive, locally advanced, unresectable or metastatic urothelial carcinoma or a history of this disease (i.e., ≥ T2);
• \. Those who have received any BCG treatment for NMIBC in the past;
• \. Those who know or suspect that abnormal conditions such as bladder perforation occur during surgery;
• \. Those who suspect that the surgical wound has not healed or the urinary tract mucosa is damaged;
• \. Those who have been assessed by the investigator to be accompanied by cystitis (such as urinary frequency, urgency, dysuria, etc.), or have received other bladder infusion drugs and have severe bladder irritation, which is expected to affect the evaluation of this study;
• \. In addition to immediate postoperative intravesical chemotherapy, patients who have received other systemic anti-tumor treatments such as chemotherapy, radiotherapy, and immunotherapy for the disease under study;
• \. Pregnant or lactating women;
• \. Those who cannot guarantee effective contraception during the trial period to 6 months after the last dose;
• \. Received treatment with other clinical trial drugs (except placebo) or clinical trial devices within 3 months before the first dose;
• \. Those who have a history of alcoholism, drug abuse or drug abuse within 6 months before screening;
• \. Presence of any of the following: positive human immunodeficiency virus (HIV) antibody, positive syphilis-specific antibody, active hepatitis B (hepatitis B surface antigen (HBsAg) positive and hepatitis B virus deoxyribonucleic acid (DNA) copy number ≥200 IU/mL or 1000 copies/mL), hepatitis C virus (HCV) antibody positive and HCV virus copy number higher than the upper limit of normal in the research center≥ 10\^3/mL;

Sponsors & Collaborators

• Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.: lead

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, China

Location

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Interventions

Therapeutic Uses

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Pharmacologic Actions; Chemical Actions and Uses

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2024
• First Posted: December 24, 2024
• Study Start: April 8, 2025
• Primary Completion (Estimated): April 30, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: April 27, 2026

Record last verified: 2026-04

Locations

CN (1)